Fludase Treatment

Fludase for the Treatment of Influenza

Fludase is a new First-in-Class broad spectrum host directed influenza investigational antiviral

Fludase is active in vitro against all strains of influenza isolated tested to date including H5N1, H1N1, H7N9 and drug resistant viral strains and thus may be useful for pandemic stockpiling

U.S. Government has provided strong funding support (over $100 Million) for the development of Fludase

Ansun has completed a Pivotol Phase 2B trial in influenza